RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE
Clinical trials for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE trials appear
Sign up with your email to follow new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo may bridge more patients to lifesaving CAR-T therapy
Disease control Recruiting nowThis study tests whether giving two drugs—golcadomide and rituximab—before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to keep the disease in check so more patients can qualify for and rec…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug targets Hard-to-Treat lymphoma in early trial
Disease control Recruiting nowThis early-phase trial is testing a drug called tegavivint in about 18 people whose large B-cell lymphoma has come back or stopped responding to standard treatments. The drug works by blocking certain enzymes that cancer cells need to grow. The main goals are to find the safest d…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated May 13, 2026 15:59 UTC